Karen E. Moeller

1.1k total citations
22 papers, 655 citations indexed

About

Karen E. Moeller is a scholar working on Psychiatry and Mental health, Pharmacology and Toxicology. According to data from OpenAlex, Karen E. Moeller has authored 22 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Psychiatry and Mental health, 5 papers in Pharmacology and 5 papers in Toxicology. Recurrent topics in Karen E. Moeller's work include Bipolar Disorder and Treatment (4 papers), Forensic Toxicology and Drug Analysis (4 papers) and Schizophrenia research and treatment (4 papers). Karen E. Moeller is often cited by papers focused on Bipolar Disorder and Treatment (4 papers), Forensic Toxicology and Drug Analysis (4 papers) and Schizophrenia research and treatment (4 papers). Karen E. Moeller collaborates with scholars based in United States and Spain. Karen E. Moeller's co-authors include Kelly C. Lee, Julie C. Kissack, Rabia S. Atayee, Barbara Woods, Theresa I. Shireman, Brittany L. Melton, Sally K. Rigler, Barry I. Liskow, Eugene H. Makela and Niaman Nazir and has published in prestigious journals such as Mayo Clinic Proceedings, Schizophrenia Research and The Journal of Clinical Psychiatry.

In The Last Decade

Karen E. Moeller

21 papers receiving 606 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen E. Moeller United States 9 210 173 162 108 100 22 655
Julie C. Kissack United States 7 215 1.0× 200 1.2× 120 0.7× 108 1.0× 84 0.8× 14 645
Amélie Daveluy France 14 267 1.3× 242 1.4× 132 0.8× 89 0.8× 67 0.7× 78 602
Jonathan Brett Australia 19 103 0.5× 166 1.0× 207 1.3× 139 1.3× 85 0.8× 80 1.1k
Jennifer L. Pilgrim Australia 20 278 1.3× 339 2.0× 154 1.0× 107 1.0× 74 0.7× 38 903
Trond Oskar Aamo Norway 17 88 0.4× 137 0.8× 149 0.9× 105 1.0× 130 1.3× 35 795
Caroline Victorri‐Vigneau France 19 195 0.9× 257 1.5× 203 1.3× 214 2.0× 107 1.1× 138 1.3k
Christopher Hoyte United States 15 224 1.1× 118 0.7× 346 2.1× 113 1.0× 122 1.2× 63 1.1k
Pirkko Kriikku Finland 15 387 1.8× 209 1.2× 126 0.8× 76 0.7× 37 0.4× 47 668
Isabelle Giraudon Portugal 18 400 1.9× 264 1.5× 189 1.2× 273 2.5× 77 0.8× 43 998
Craig G. Smollin United States 15 169 0.8× 93 0.5× 108 0.7× 31 0.3× 81 0.8× 41 619

Countries citing papers authored by Karen E. Moeller

Since Specialization
Citations

This map shows the geographic impact of Karen E. Moeller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen E. Moeller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen E. Moeller more than expected).

Fields of papers citing papers by Karen E. Moeller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen E. Moeller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen E. Moeller. The network helps show where Karen E. Moeller may publish in the future.

Co-authorship network of co-authors of Karen E. Moeller

This figure shows the co-authorship network connecting the top 25 collaborators of Karen E. Moeller. A scholar is included among the top collaborators of Karen E. Moeller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen E. Moeller. Karen E. Moeller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Melton, Brittany L., et al.. (2024). Antipsychotics in child and adolescent patients with major depressive disorder: A retrospective analysis of prescribing patterns. Mental Health Clinician. 14(1). 10–16. 1 indexed citations
2.
Moeller, Karen E., et al.. (2024). Exploring the harm reduction paradigm: the role of Board-Certified Psychiatric Pharmacists. Mental Health Clinician. 14(4). 253–266.
3.
Moeller, Karen E., et al.. (2023). Consumer perception, knowledge, and uses of cannabidiol. Mental Health Clinician. 13(5). 217–224. 7 indexed citations
4.
Moeller, Karen E., et al.. (2023). Pediatric Neuromyelitis Optica Spectrum Disorder. Seminars in Pediatric Neurology. 46. 101051–101051. 1 indexed citations
5.
Melton, Brittany L., et al.. (2023). Comparison of inpatient psychiatric medication management in gender diverse youth with cisgender peers. Mental Health Clinician. 13(4). 169–175. 1 indexed citations
6.
Melton, Brittany L., et al.. (2022). Initiation of Antipsychotic Treatment for Amphetamine Induced Psychosis and Its Impact on Length of Stay. Journal of Pharmacy Practice. 36(6). 1324–1329. 1 indexed citations
7.
Moeller, Karen E., et al.. (2021). Assessing pharmacy students' knowledge and perceptions of urine drug testing following a pharmacy skills laboratory. Currents in Pharmacy Teaching and Learning. 13(5). 530–535. 3 indexed citations
8.
Moeller, Karen E., et al.. (2019). A nationwide survey of pharmacy students’ knowledge and perceptions regarding medical cannabis. Journal of the American Pharmacists Association. 60(1). 218–224.e3. 14 indexed citations
9.
Moeller, Karen E., Julie C. Kissack, Rabia S. Atayee, & Kelly C. Lee. (2017). Clinical Interpretation of Urine Drug Tests. Mayo Clinic Proceedings. 92(5). 774–796. 111 indexed citations
10.
Moeller, Karen E., et al.. (2017). Medical Students’ Perceptions on the Role of Pharmacists. Journal of Pharmacy Practice. 31(6). 623–628. 7 indexed citations
11.
Moeller, Karen E., et al.. (2016). Psychotropic medication use in hospitalized patients with borderline personality disorder. Mental Health Clinician. 6(2). 68–74. 5 indexed citations
12.
Moeller, Karen E. & Barbara Woods. (2015). Pharmacy Students’ Knowledge and Attitudes Regarding Medical Marijuana. American Journal of Pharmaceutical Education. 79(6). 85–85. 48 indexed citations
13.
Moeller, Karen E.. (2013). Favorable pregnancy outcomes following continual intramuscular lorazepam use in late pregnancy. Mental Health Clinician. 3(2). 96–98. 1 indexed citations
14.
Moeller, Karen E., et al.. (2010). Pharmacy Students' Knowledge of Black Box Warnings. American Journal of Pharmaceutical Education. 74(1). 5–5. 6 indexed citations
15.
Moeller, Karen E., et al.. (2010). Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research. 126(1-3). 117–123. 22 indexed citations
16.
Moeller, Karen E., Kelly C. Lee, & Julie C. Kissack. (2008). Urine Drug Screening: Practical Guide for Clinicians. Mayo Clinic Proceedings. 83(1). 66–76. 354 indexed citations
17.
Moeller, Karen E., Kelly C. Lee, & Julie C. Kissack. (2008). “Practical Guide” to Urine Drug Screening Clarified–Reply–I. Mayo Clinic Proceedings. 83(7). 849–849. 1 indexed citations
18.
Moeller, Karen E., Theresa I. Shireman, & Barry I. Liskow. (2006). Relapse Rates in Patients With Schizophrenia Receiving Aripiprazole in Comparison With Other Atypical Antipsychotics. The Journal of Clinical Psychiatry. 67(12). 1942–1947. 15 indexed citations
19.
Kalsekar, Iftekhar, Eugene H. Makela, & Karen E. Moeller. (2003). Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia. Current Therapeutic Research. 64(8). 538–550. 3 indexed citations
20.
Moeller, Karen E., et al.. (2003). Prolonged Thrombocytopenia Associated with Isotretinoin. Annals of Pharmacotherapy. 37(11). 1622–1624. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie C. Kissack Breakdown of academic impact, for papers by Amélie Daveluy Breakdown of academic impact, for papers by Jonathan Brett Breakdown of academic impact, for papers by Jennifer L. Pilgrim Breakdown of academic impact, for papers by Trond Oskar Aamo Breakdown of academic impact, for papers by Caroline Victorri‐Vigneau Breakdown of academic impact, for papers by Christopher Hoyte Breakdown of academic impact, for papers by Pirkko Kriikku Breakdown of academic impact, for papers by Isabelle Giraudon Breakdown of academic impact, for papers by Craig G. Smollin
Rankless by CCL
2026